Phaseline

Targets › CTXM

CTXM: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Infectious disease; next expected readout Apr 2027.

Open in Phaseline: the race on CTXM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Pfizeraztreonam-avibactam (ATM-AVI)
β-lactam antibiotic (aztreonam) combined with β-lactamase inhibitor (avibactam)
MMPBLA, CTXMPhase 2Gram-negative Bacterial InfectionApr 2027

Conditions

Gram-negative Bacterial Infection (1)

Modalities

small molecule (1)

Companies

Pfizer (1)

Related targets

MMPBLA (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.